- Home
- SLSN vs INBX Comparison
SLSN vs INBX Comparison
Compare SLSN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSN
- INBX
- Stock Information
- Founded
- SLSN 1989
- INBX 2010
- Country
- SLSN United States
- INBX United States
- Employees
- SLSN N/A
- INBX N/A
- Industry
- SLSN
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SLSN
- INBX Health Care
- Exchange
- SLSN NYSE
- INBX Nasdaq
- Market Cap
- SLSN 218.7M
- INBX 178.5M
- IPO Year
- SLSN N/A
- INBX 2020
- Fundamental
- Price
- SLSN $3.86
- INBX $13.47
- Analyst Decision
- SLSN
- INBX Hold
- Analyst Count
- SLSN 0
- INBX 1
- Target Price
- SLSN N/A
- INBX N/A
- AVG Volume (30 Days)
- SLSN 84.5K
- INBX 102.3K
- Earning Date
- SLSN 05-05-2025
- INBX 05-14-2025
- Dividend Yield
- SLSN N/A
- INBX N/A
- EPS Growth
- SLSN N/A
- INBX N/A
- EPS
- SLSN 0.05
- INBX 111.58
- Revenue
- SLSN $57,104,000.00
- INBX $200,000.00
- Revenue This Year
- SLSN N/A
- INBX N/A
- Revenue Next Year
- SLSN N/A
- INBX N/A
- P/E Ratio
- SLSN $76.37
- INBX $0.12
- Revenue Growth
- SLSN 51.44
- INBX N/A
- 52 Week Low
- SLSN $1.21
- INBX $10.80
- 52 Week High
- SLSN $16.56
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- SLSN N/A
- INBX 59.06
- Support Level
- SLSN N/A
- INBX $12.25
- Resistance Level
- SLSN N/A
- INBX $13.88
- Average True Range (ATR)
- SLSN 0.00
- INBX 0.70
- MACD
- SLSN 0.00
- INBX 0.20
- Stochastic Oscillator
- SLSN 0.00
- INBX 86.66
About SLSN SOLESENCE INC
Solesence Inc is a scientifically driven health care solutions company across beauty and life science categories, protecting skin from environmental aggressors and enhancing the aesthetic appeal of healthy products. The group is engaged in the beauty category that develops and manufactures clean, inclusive, mineral-based skincare and makeup products at the forefront of skin health. Its brands are Stress Defense, Kleair, and Bloom.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.